Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Turnidge

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Communicable Diseases Intelligence Quarterly Report|October 29, 2004
Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverageMichael Watson, Kathy Bayley, Jan M Bell, et al.
Communicable Diseases Intelligence Quarterly Report|March 5, 2005
Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine programMichael Watson, Paul Roche, Kathy Bayley, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2026
Novel EUCAST-approved quality control range for Escherichia coli ATCC® 25922 and cefoperazone 30 µg discsJohanna Jahnen, Erika Matuschek, Leonard Limpinsel, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 10, 2020
What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?Thomas Schön, Claudio Umberto Köser, Jim Werngren, et al.
BMC Infectious Diseases|March 3, 2016
SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patientsJason A Roberts, Gordon Y S Choi, Gavin M Joynt, et al.
The Journal of Antimicrobial Chemotherapy|October 15, 2020
Determination of norvancomycin epidemiological cut-off values (ECOFFs) for Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominisQiwen Yang, Xue Li, Peiyao Jia, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2023
Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilutionGabrielle Fröberg, Florian P Maurer, Erja Chryssanthou, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 16, 2026
The role of whole genome sequencing in antimicrobial susceptibility prediction of bacteria: 2025 update from the EUCAST SubcommitteeØrjan Samuelsen, Carla López-Causapé, Frank Møller Aarestrup, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2020
The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy StudyJason A Roberts, Gavin M Joynt, Anna Lee, et al.
Intensive Care Medicine|August 13, 2025
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapyJason A Roberts, Marta Ulldemolins, Xin Liu, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Communicable Diseases Intelligence Quarterly Report|October 29, 2004
Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverageMichael Watson, Kathy Bayley, Jan M Bell, et al.
Communicable Diseases Intelligence Quarterly Report|March 5, 2005
Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine programMichael Watson, Paul Roche, Kathy Bayley, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2026
Novel EUCAST-approved quality control range for Escherichia coli ATCC® 25922 and cefoperazone 30 µg discsJohanna Jahnen, Erika Matuschek, Leonard Limpinsel, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 10, 2020
What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?Thomas Schön, Claudio Umberto Köser, Jim Werngren, et al.
BMC Infectious Diseases|March 3, 2016
SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patientsJason A Roberts, Gordon Y S Choi, Gavin M Joynt, et al.
The Journal of Antimicrobial Chemotherapy|October 15, 2020
Determination of norvancomycin epidemiological cut-off values (ECOFFs) for Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominisQiwen Yang, Xue Li, Peiyao Jia, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2023
Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilutionGabrielle Fröberg, Florian P Maurer, Erja Chryssanthou, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 16, 2026
The role of whole genome sequencing in antimicrobial susceptibility prediction of bacteria: 2025 update from the EUCAST SubcommitteeØrjan Samuelsen, Carla López-Causapé, Frank Møller Aarestrup, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2020
The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy StudyJason A Roberts, Gavin M Joynt, Anna Lee, et al.
Intensive Care Medicine|August 13, 2025
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapyJason A Roberts, Marta Ulldemolins, Xin Liu, et al.
Pageof 9